Literature DB >> 1709873

12(R)-hydroxyeicosatrienoic acid, a potent chemotactic and angiogenic factor produced by the cornea.

J L Masferrer1, J A Rimarachin, M E Gerritsen, J R Falck, P Yadagiri, M W Dunn, M Laniado-Schwartzman.   

Abstract

Human and bovine corneal epithelial cytochrome P450 convert arachidonic acid to compound D [12(R)-hydroxy-5,8,14(Z,Z,Z)-eicosatrienoic acid], a metabolite with inflammatory properties including vasodilatation and breakdown of the blood-aqueous barrier. Angiogenic properties of the endogenous compound D and the synthetic enantiomers DR and DS were examined using the corneal micropocket technique. The synthetic compound DR was as active as the endogenously formed compound D. Neovascularization of the cornea was found in all the implants containing as little as 0.5 micrograms of compound DR. In contrast, the stereoisomer DS at the same concentration (0.5 micrograms) was inactive. Since angiogenesis can be secondary to a local inflammatory response, we evaluated the effects of compound DR and its stereoisomer DS on human neutrophil chemotaxis by using a modified Boyden chamber technique. DR, but not DS, was found to be a potent chemotactic factor, exhibiting dose-dependent neutrophil chemotaxis with significant responses observed at doses as low as 10(-11) M, a concentration at which leukotriene B4 does not exhibit significant chemotactic activity. Therefore, compound D produced by the cornea may qualify as an intrinsic corneal angiogenic factor which, in association with other inflammatory mechanisms, account for the growth of new vessels in the cornea that appear in chronic inflammation or in the reparative stages of an acute process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709873     DOI: 10.1016/0014-4835(91)90037-f

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

1.  Targeted knock-down of a structurally atypical zebrafish 12S-lipoxygenase leads to severe impairment of embryonic development.

Authors:  Ulrike Haas; Elisabeth Raschperger; Mats Hamberg; Bengt Samuelsson; Karl Tryggvason; Jesper Z Haeggström
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

3.  Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal-derived eicosanoid.

Authors:  R A Stoltz; M S Conners; M E Gerritsen; N G Abraham; M Laniado-Schwartzman
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

Review 4.  Who is the real 12-HETrE?

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-03-01       Impact factor: 3.072

5.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.

Authors:  Francesca Seta; Kiran Patil; Lars Bellner; Alexandre Mezentsev; Rowena Kemp; Michael W Dunn; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-05-21       Impact factor: 3.072

6.  Heme oxygenase-2 is a critical determinant for execution of an acute inflammatory and reparative response.

Authors:  Francesca Seta; Lars Bellner; Rita Rezzani; Raymond F Regan; Michael W Dunn; Nader G Abraham; Karsten Gronert; Michal Laniado-Schwartzman
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance.

Authors:  D C Zeldin; J D Plitman; J Kobayashi; R F Miller; J R Snapper; J R Falck; J L Szarek; R M Philpot; J H Capdevila
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

8.  The role of NF-kappaB in the angiogenic response of coronary microvessel endothelial cells.

Authors:  R A Stoltz; N G Abraham; M Laniado-Schwartzman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

9.  Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).

Authors:  H J Hussey; M C Bibby; M J Tisdale
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.